Floatz logo

THIOGUANINE ANHYDROUS

Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)

Children's Oncology GroupSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
Cytosin-Arabinosid
Northwestern University
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Idarubicine
Bruno C. Medeiros
Phase 2BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

THIOGUANINE ANHYDROUS is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
lymphoblastic lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →